ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Wyden Hearing On Taxol Agreements Mangles Facts In Attempt To Protect ‘Public Interest’

August 9, 1991

Letter to the Editor: Colleagues describe Bunn As Leader, Patient Advocate

January 12, 1996

Funding Opportunities: RFAs For Mouse Models Consortium, Urology Research Centers

August 7, 1998

Decade-Long Cover-up?

January 6, 1995

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

Society Recognizes Community Oncologists (8-page issue).

June 6, 2003